Shots:
- The US FDA has accepted BLA of Mogenry (sonpiretigene isteparvovec, MCO-010), an optogenetic gene therapy designed for vision restoration for pts with retinitis pigmentosa (RP) having severe vision loss
- BLA was supported by the P-I/IIa trial, & the P-IIb/III (RESTORE) trial, where RESTORE met its 1 & 2EPs, showing improvements in visual acuity at wks. 52 & 76
- Mogenry is a one-time intravitreal optogenetic gene therapy using Nanoscope’s MCO platform to make surviving bipolar retinal cells light-sensitive, helping restore visual signaling after photoreceptor loss
Ref: Businesswire | Image: Nanoscope Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
